![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Kbw Regional Banking Index | DOWI:KRX | Dow Jones Indices | Index |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
REMINDER: Keryx Biopharmaceuticals CEO to Provide KRX-101 Update Today at the Rodman & Renshaw Techvest Healthcare Conference NEW YORK, Oct. 21 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX), a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, wishes to remind all interested parties that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including an update of its newly initiated Phase II/III clinical program for its lead drug candidate, KRX-101, at the Rodman & Renshaw Techvest Healthcare Conference in Boston. Mr. Weiss's presentation will take place today, Tuesday, October 21, 2003, at 12:40 p.m. EDT, in Salons J-L of the Boston Marriott Long Wharf Hotel. A live audio webcast will be available during the presentation at http://www.wallstreetwebcasting.com/webcast/rrshq/kerx / and will be archived for a period of 60 days. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life- threatening diseases, including diabetes and cancer. Keryx is developing KRX- 101 (sulodexide), a novel first-in-class oral heparinoid compound, for the treatment of diabetic nephropathy, for which Keryx is currently planning its U.S.-based Phase II/III clinical program. Keryx also has an active in- licensing program designed to identify and acquire clinical-stage drug candidates. Additionally, Keryx is seeking partners for its KinAce(TM) drug discovery technology and related products. Keryx Biopharmaceuticals is headquartered in New York City. KERYX CONTACT: Ron Bentsur Vice President - Finance & Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: ron@keryx.com SOURCE Keryx Biopharmaceuticals, Inc. -0- 10/21/2003 /CONTACT: Ron Bentsur, Vice President - Finance & Investor Relations, Keryx Biopharmaceuticals, Inc., +1-212-531-5965 or ron@keryx.com/ /Web site: http://www.wallstreetwebcasting.com/webcast/rrshq/kerx / (KERX) END
1 Year Kbw Regional Banking Index Chart |
1 Month Kbw Regional Banking Index Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions